Moderna (mrna) Q4 income 2024

Moderna achieved revenues in the fourth quarter on Friday, which exceeded estimates, but lost more than expected for the period, since the biotech company further reduce the costs and demand for its covid vaccines.

It is another quarter of growing pain for the company, which is for the introduction of new products and the recovery of the rapid decline of his once fighting covid business.

Moderna’s shares rose by more than 3%on Friday.

Moderna recorded a net loss of $ 1.12 billion or $ 2.91 per share for the fourth quarter of 2024. This corresponds to the net result of $ 217 million or 55 cents per share, which was reported for the period from the previous year.

The company said that the quarterly loss contains a not numerous fee of around $ 238 million in connection with the termination of a contract manufacturing contract.

In an interview, the CFO of Moderna, Jamey Mock, said that one of the most important findings from the results of the entire year 2024 reduced costs compared to 2023 by 27%. By the end of 2025, Moderna expects to reduce the cost of 1 USD billions compared to 2024.

Moderna confirmed its product sales instructions for the year 2025 from $ 1.5 to 2.5 billion, most of which will take place in the second half of the year. Moderna expects that in the first half of the year due to the seasonal demand for respiratory products, which usually rise in autumn and winter, only $ 200 million expects only 200 million US dollars.

The company reduced its sales instructions from 2025 in January by around 1 billion US dollars, which reduces its shares. The share has now declined by more than 20% for the year.

At that time, Moderna pointed out increased competition on the Covid market, the vaccination rates, the time of production contracts with a handful of countries and the uncertainty about what the consultants for the control and prevention of diseases for the resumption of syncytial virus – Shots of the respiratory tract would recommend.

“If these potential headwinds all hit, this would bring us to the bottom of our instructions,” Mock told CNBC and added that the company hopes to “combat” the challenges.

Moderna reported for the fourth quarter that ended on December 31st Compared to the expectations of Wall Street, LSEG is based on a survey of LSEG analysts:

• Loss per share: USD 2.91 compared to an expected loss of $ 2.68
• Revenue: 966 million US dollars are expected compared to USD 942.8 million

Moderna generated sales with $ 966 million in the fourth quarter, less than half of the $ 2.8 billion, which it recorded in the same period a year ago.

The vast majority of this total amount came from the Covid shot, which declined 923 million US dollars, which corresponds to a decline of 66% compared to the previous year. This includes sales of US $ 244 million and $ 679 million from international markets.

According to StreetCcount estimates, the analysts had expected sales of 909 million US dollars for the quarter.

Moderna said that the decline was mainly due to the earlier introduction of the latest iteration of his Covid shot last year, which shifted sales into the third quarter. The US Food and Drug Administration approved the new vaccine three weeks earlier than in 2023, so Moderna “” encountering demand before the fourth quarter, “added the company.

The sales of Covid vaccines fell back internationally, since according to Moderna, the company continued to carry out pre -purchase agreements with certain countries.

The sales with the fourth quarter of the company also included $ 15 million for the turnover of its RSV shot in US dollars, which entered seniors in the fall and winter after winning the approval in May. It is the second approved Moderna product according to its Covid vaccine.

According to StreetCcount estimates, analysts had expected sales of $ 13 million for the RSV vaccine. Modernas RSV shot is approved in the United States, the USA, the European Union, in Canada, Norway, Iceland and in the Qatar up to the age of 60.

The company uses a pipeline that is located around its Messenger RNA platform, namely the technology used in both products. Moderna plans to improve its portfolio with 10 new product permits over the next three years.

In the fourth quarter, Moderna submitted three MRNA products for regulatory approval, including the next generation Covid shot, the combination of covid and the flu and RSV vaccine for adults aged 18 to 59. Moderna expects a decision from the FDA on the next generation of the next generation in May and a potential approval for the RSV shot in June in June.

Moderna also develops an independent flu vaccination, a personalized cancer vaccine with Merck and recordings for latent viruses. Some of these products will start data Lehouts later this year, says Mock.

The sales costs for the fourth quarter were $ 739 million, which decreased from 20% compared to the same period in the previous year. Among other things, this includes $ 193 million in spelling of unused doses of the Covid vaccine.

The research and development costs decreased by 20% to 1.1 billion US dollars compared to the same period from 2023. Moderna said that the decline is primarily due to lower clinical development and manufacturing costs for the COVID, RSV, flu and combination programs and was partly compensated for by increased expenses on other new experimental products.

In the meantime, sales, general and administrative costs for the period decreased by 25% to USD 351 million compared to the fourth quarter of 2023. SG & A expenditure usually includes the costs for the promotion, sale and provision of a company’s products and services.